Choreo LLC Takes Position in ARK Genomic Revolution ETF (BATS:ARKG)

Choreo LLC acquired a new position in ARK Genomic Revolution ETF (BATS:ARKG) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 13,501 shares of the company’s stock, valued at approximately $314,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Principal Securities Inc. purchased a new position in ARK Genomic Revolution ETF during the 4th quarter valued at about $32,000. Chris Bulman Inc acquired a new position in ARK Genomic Revolution ETF in the 2nd quarter valued at approximately $36,000. Tidemark LLC purchased a new stake in ARK Genomic Revolution ETF in the 4th quarter worth approximately $48,000. EverSource Wealth Advisors LLC acquired a new stake in shares of ARK Genomic Revolution ETF during the 1st quarter valued at $49,000. Finally, Larson Financial Group LLC grew its holdings in shares of ARK Genomic Revolution ETF by 4,576.1% during the 2nd quarter. Larson Financial Group LLC now owns 3,320 shares of the company’s stock valued at $78,000 after acquiring an additional 3,249 shares in the last quarter.

ARK Genomic Revolution ETF Stock Performance

BATS ARKG opened at $26.29 on Wednesday. The stock has a fifty day moving average of $25.64 and a two-hundred day moving average of $25.88.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.